Entegrion landed a $43.7 million dollar contract with the Dept. of Defense for its Resusix proprietary dehydrated pathogen-inactivated human plasma.
Resusix holds promise as a substitute for fresh frozen plasma in certain situations. The Defense Dept. contract will fund Resusix’s development through Phase III clinical trials and biological license application.
"Our focus is to offer a safer and more effective alternative for frozen blood plasma,which often is not readily available in austere and remote locations." Joseph DaCorta, Entegrion’s Chief Technology office, said in prepared remarks. "In addition, Resusix has tremendous potential for serving unmet medical needs in global health settings."
Sign up to get our free newsletters delivered right to your inbox.
The Durham, N.C.-based company expects ten to 15 clinical investigation sites to participate in each phase of the product’s clinical development.
Here’s a roundup of other dealflow and investment news:
- Bridge Bank provides $2.5 million credit line to Image Stream Medical
Bridge Capital Holdings (NASDAQ: BBNK) subsidiary, Bridge Bank, provided a $2.5 million line of credit to Image Stream Medical.
Read more - Spire Biomedical awarded NIH grant for dental arch wire coatings
Spire Biomedical landed a nine-month Small Business Innovation Research grant from the National Institute of Dental and Craniofacial Research.
Read more - TearScience lands $15 million for dry eye treatment
Medical device company Tear Science secured $15 million in debt financing to further its dry eye treatments.
Read more - LambdaVision Inc receives pre-seed financing for retinal implant
UConn-grown medical device startup, Lambda Vision Inc. received $40,000 in financing from Connecticut Innovations to develop a retinal implant.
Read more - Touch Bionics lands funding for global expansion
Prosthetic tech company Touch Bionics secured nearly $4 million to finance its global expansion.
Read more - NxThera raises $21.6 million in series B financing
Men’s health company NxThera raised $21.6 million in series B financing for its Rezum vapor ablation device.
Read more - IPG secures three-fold credit increase from Silicon Valley Bank
Implantable Provider Group secured a three-fold increase in their line of credit arrangement with Silicon Valley Bank.
Read more - CV Ingenuity raises $16 million in Series B
Privately-held CV Ingenuity raised $16 million in Series B financing round. Investors were led by VC New Enterprise Associates.
Read more - BARDA funds development of five radiation protection drugs
The U.S. Department of Health’s Biomedical Advanced Research and Development Authority handed out development contracts totaling $56.3 million for the treatment of injuries related to radiation syndrome.
Read more
